Variant Allele of HSD3B1 Increases Progression to Castration-Resistant Prostate Cancer
文献类型：期刊论文
| 作者 | Wu, G; Huang, SS; Nastiuk, KL; Li, JL; Gu, J; Wu, M; Zhang, QM; Lin, HQ; Wu, DL |
| 刊名 | PROSTATE
 |
| 出版日期 | 2015 |
| 卷号 | 75期号:7页码:777-782 |
| 关键词 | HSD3B germline mutation prostate cancer castration-resistant prostate cancer androgen deprivation therapy |
| 通讯作者 | Wu, DL (reprint author), Tongji Univ, Tongji Hosp, Sch Med, Dept Urol, XinChun Rd 389, Shanghai 200092, Peoples R China.,hqlin@sibcb.ac.cn ; wudenglong2013@126.com |
| 英文摘要 | BACKGROUND3-hydroxysteroid dehydrogenase type 1 (3HSD1), which is a rate-limiting enzyme that catalyzes the conversion of adrenal-derived steroid dehydroepiandrosterone to dihydrotestosterone (DHT), may be a promising target for treating castration-resistant prostate cancer (CRPC). METHODSFrom 2004 to 2011, a total of 103 consecutive patients presenting with advanced prostate cancer were included in this study. All patients were treated with surgical castration as androgen-deprivation therapy (ADT). Germline DNA was extracted from archived tissue from each patient and sequenced. PSA half-time (representing rate to PSA nadir after ADT), the incidence of, and time to CRPC occurrence, and cause-specific mortality rates were determined during the 3-10 years follow-up. The perioperative data and postoperative outcomes are compared. The patients were retrospectively analyzed for survival time. RESULTSOf the 103 patient samples analyzed, 18 harbored a heterozygous variant (1245C) HSD3B1 gene, while 85 patients were homozygous wild-type (1245A) for HSD3B1. The two groups were homogenous for age, PSA, Gleason and metastases rate preoperatively. The incidence of CRPC observed in the variant group was significantly higher than that of wild-type group (100% vs. 64.7%, respectively; P=0.003). Despite this higher incidence of CRPC, there were no significant differences in time to develop CRPC, or in cause-specific mortality. Further, neither PSA half-time, nor time to biochemical recurrence were different between the variant and wild-type groups. CONCLUSIONProstate cancer patients who harbored the heterozygous variant HSD3B1 (1245C) are more likely to develop to CRPC, but do not have shorter time to biochemical recurrence, shorter survival time or higher mortality risk. Prostate 75:777-782, 2015. (c) 2015 Wiley Periodicals, Inc. |
| 学科主题 | Endocrinology & Metabolism; Urology & Nephrology |
| 类目[WOS] | Endocrinology & Metabolism ; Urology & Nephrology |
| 关键词[WOS] | 3-BETA-HYDROXYSTEROID DEHYDROGENASE ; ANDROGEN RECEPTOR ; EPITHELIAL-CELLS ; EXPRESSION ; MECHANISMS ; INTERLEUKIN-4 ; TRANSCRIPTION ; INDUCTION ; LINES |
| 收录类别 | SCI |
| 语种 | 英语 |
| WOS记录号 | WOS:000352716300010 |
| 版本 | 出版稿 |
| 源URL | [http://202.127.25.143/handle/331003/81]  |
| 专题 | 上海生化细胞研究所_上海生科院生化细胞研究所 |
| 推荐引用方式 GB/T 7714 | Wu, G,Huang, SS,Nastiuk, KL,et al. Variant Allele of HSD3B1 Increases Progression to Castration-Resistant Prostate Cancer[J]. PROSTATE,2015,75(7):777-782. |
| APA | Wu, G.,Huang, SS.,Nastiuk, KL.,Li, JL.,Gu, J.,...&Wu, DL.(2015).Variant Allele of HSD3B1 Increases Progression to Castration-Resistant Prostate Cancer.PROSTATE,75(7),777-782. |
| MLA | Wu, G,et al."Variant Allele of HSD3B1 Increases Progression to Castration-Resistant Prostate Cancer".PROSTATE 75.7(2015):777-782. |
入库方式： OAI收割
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。